1045 related articles for article (PubMed ID: 16916931)
21. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment.
Cekic C; Linden J
Cancer Res; 2014 Dec; 74(24):7239-49. PubMed ID: 25341542
[TBL] [Abstract][Full Text] [Related]
22. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity.
Li N; Mu L; Wang J; Zhang J; Xie X; Kong Q; Tang W; Yao X; Liu Y; Wang L; Wang G; Wang D; Jin L; Sun B; Li H
Eur J Immunol; 2012 May; 42(5):1140-51. PubMed ID: 22539289
[TBL] [Abstract][Full Text] [Related]
23. Small molecule AZD4635 inhibitor of A
Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
[TBL] [Abstract][Full Text] [Related]
24. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.
Sitkovsky MV; Hatfield S; Abbott R; Belikoff B; Lukashev D; Ohta A
Cancer Immunol Res; 2014 Jul; 2(7):598-605. PubMed ID: 24990240
[TBL] [Abstract][Full Text] [Related]
25. [Blocking Adenosine/A2AR Pathway for Cancer Therapy].
Liu J; Shi Y; Liu X; Zhang D; Bai Y; Xu Y; Wang M
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):460-467. PubMed ID: 35899442
[TBL] [Abstract][Full Text] [Related]
26. Adenosine negative feedback on A2A adenosine receptors mediates hyporesponsiveness in chronically septic mice.
Belikoff B; Hatfield S; Sitkovsky M; Remick DG
Shock; 2011 Apr; 35(4):382-7. PubMed ID: 21192284
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.
Fallah-Mehrjardi K; Mirzaei HR; Masoumi E; Jafarzadeh L; Rostamian H; Khakpoor-Koosheh M; Alishah K; Noorbakhsh F; Hadjati J
Immunol Lett; 2020 Jul; 223():44-52. PubMed ID: 32289340
[TBL] [Abstract][Full Text] [Related]
28. Choroid plexus-selective inactivation of adenosine A
Zheng W; Feng Y; Zeng Z; Ye M; Wang M; Liu X; Tang P; Shang H; Sun X; Lin X; Wang M; Li Z; Weng Y; Guo W; Vakal S; Chen JF
J Neuroinflammation; 2022 Feb; 19(1):52. PubMed ID: 35180864
[TBL] [Abstract][Full Text] [Related]
29. Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity.
Ferreira DG; Batalha VL; Vicente Miranda H; Coelho JE; Gomes R; Gonçalves FQ; Real JI; Rino J; Albino-Teixeira A; Cunha RA; Outeiro TF; Lopes LV
Cereb Cortex; 2017 Jan; 27(1):718-730. PubMed ID: 26534909
[TBL] [Abstract][Full Text] [Related]
30. NOX2 Activation of Natural Killer T Cells Is Blocked by the Adenosine A2A Receptor to Inhibit Lung Ischemia-Reperfusion Injury.
Sharma AK; LaPar DJ; Stone ML; Zhao Y; Mehta CK; Kron IL; Laubach VE
Am J Respir Crit Care Med; 2016 May; 193(9):988-99. PubMed ID: 26757359
[TBL] [Abstract][Full Text] [Related]
31. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage.
Fink JS; Kalda A; Ryu H; Stack EC; Schwarzschild MA; Chen JF; Ferrante RJ
J Neurochem; 2004 Feb; 88(3):538-44. PubMed ID: 14720203
[TBL] [Abstract][Full Text] [Related]
32. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.
Beavis PA; Henderson MA; Giuffrida L; Mills JK; Sek K; Cross RS; Davenport AJ; John LB; Mardiana S; Slaney CY; Johnstone RW; Trapani JA; Stagg J; Loi S; Kats L; Gyorki D; Kershaw MH; Darcy PK
J Clin Invest; 2017 Mar; 127(3):929-941. PubMed ID: 28165340
[TBL] [Abstract][Full Text] [Related]
33. Combined Deficiency of the Melanocortin 5 Receptor and Adenosine 2A Receptor Unexpectedly Provides Resistance to Autoimmune Disease in a CD8
McDonald T; Muhammad F; Peters K; Lee DJ
Front Immunol; 2021; 12():742154. PubMed ID: 34867964
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological preconditioning with adenosine A(1) receptor agonist suppresses cellular immune response by an A(2A) receptor dependent mechanism.
Naamani O; Chaimovitz C; Douvdevani A
Int Immunopharmacol; 2014 May; 20(1):205-12. PubMed ID: 24560904
[TBL] [Abstract][Full Text] [Related]
35. Adenosine receptors as potential targets in melanoma.
Montinaro A; Iannone R; Pinto A; Morello S
Pharmacol Res; 2013 Oct; 76():34-40. PubMed ID: 23856527
[TBL] [Abstract][Full Text] [Related]
36. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes.
Yang Z; Day YJ; Toufektsian MC; Xu Y; Ramos SI; Marshall MA; French BA; Linden J
Circulation; 2006 Nov; 114(19):2056-64. PubMed ID: 17060376
[TBL] [Abstract][Full Text] [Related]
37. From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy.
Lukashev D; Sitkovsky M; Ohta A
Purinergic Signal; 2007 Mar; 3(1-2):129-34. PubMed ID: 18404426
[TBL] [Abstract][Full Text] [Related]
38. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice.
Armstrong JM; Chen JF; Schwarzschild MA; Apasov S; Smith PT; Caldwell C; Chen P; Figler H; Sullivan G; Fink S; Linden J; Sitkovsky M
Biochem J; 2001 Feb; 354(Pt 1):123-30. PubMed ID: 11171087
[TBL] [Abstract][Full Text] [Related]
39. Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy.
Masjedi A; Ahmadi A; Ghani S; Malakotikhah F; Nabi Afjadi M; Irandoust M; Karoon Kiani F; Heydarzadeh Asl S; Atyabi F; Hassannia H; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
Nanomedicine; 2020 Oct; 29():102240. PubMed ID: 32553948
[TBL] [Abstract][Full Text] [Related]
40. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells.
Masoumi E; Jafarzadeh L; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
J Exp Clin Cancer Res; 2020 Mar; 39(1):49. PubMed ID: 32151275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
